Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi

FETID

書目名稱Chemotherapy for Leukemia影響因子(影響力)




書目名稱Chemotherapy for Leukemia影響因子(影響力)學(xué)科排名




書目名稱Chemotherapy for Leukemia網(wǎng)絡(luò)公開度




書目名稱Chemotherapy for Leukemia網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Chemotherapy for Leukemia被引頻次




書目名稱Chemotherapy for Leukemia被引頻次學(xué)科排名




書目名稱Chemotherapy for Leukemia年度引用




書目名稱Chemotherapy for Leukemia年度引用學(xué)科排名




書目名稱Chemotherapy for Leukemia讀者反饋




書目名稱Chemotherapy for Leukemia讀者反饋學(xué)科排名

Perineum

有說服力

Imatinib: Clinical Pharmacology and Therapeutic Resultsd with improved prognosis in several studies. Furthermore, approximately 40% of patients who exhibited sustained deep molecular response could maintain treatment-free remission after discontinuation of imatinib. Treatment-free remission is now considered to be a new goal of tyrosine kinase inhibitor

Malaise

Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsimab resistance in the treatment of chronic lymphocytic leukemia (CLL). The characteristic toxicities of rituximab are infusion reactions, late-onset neutropenia, hepatitis B virus reactivation, and opportunistic infections..Alemtuzumab is a humanized anti-CD52 mAb and the first mAb to be approved f

針葉類的樹

Generosity

Generosity

刺耳

Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteney in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.

種子

Nelarabinetravenous (IV) infusion given over 2 h on days 1, 3, and 5 and repeated every 21 days. In pediatric patients, the recommended dose is 650 mg/m. IV given over 1 h for five consecutive days and repeated every 21 days. In a large phase II study conducted by the German Multicenter Study Group for Adult

挖掘